GF

Gary Fanger

Founder, President & CEO

Rise Therapeutics

Rise Therapeutics Pipeline

DrugIndicationPhase
R-3750Ulcerative ColitisPhase 1
R-2487Sjögren’s DiseasePhase 1 (Initiation announced)
R-5780Cancer (unspecified)Phase 1
UndisclosedRheumatoid ArthritisPhase 1 (ongoing study)